Table 1.

Characteristics of patients according to 131-I therapy response.

	CR (n = 62)	PR (n = 16)	SD (n = 8)	PD (n = 14)	p-value
Age (years)	42 ± 16	53 ± 16	46 ± 19	52 ± 15	0.06
Female gender (n)	41	10	6	11	0.7
HISTOLOGY
Papillary (n)	56	14	6	8	<0.01
Follicular (n)	6	2	2	6
STAGE
I	45	6	3	6	<0.001
II	1	6	1	2
III	12	3	2	6
IV	4	1	2	0
ATA RISK GROUP
Low	24	11	2	6	<0.01
Intermediate	28	3	2	8
High	10	2	4	0
Time interval between therapy (months)	24 (12–240)	24 (12–96)	27 (12–96)	25 (12–96)	0.5
Pre-therapy Tg level (ng/ml) offa	13.5 (5–6,000)	56.8 (8–2,107)	60.5 (12–1,000)	62.2 (5–500)	<0.001
Administered 131-I activity (GBq)	3.7 (3.7–7.4)	5.2 (3.7–7.4)	5.5 (3.7–7.4)	5.2 (3.7–7.4)	0.09
POST-THERAPY WBS
Negative	41	9	2	7	<0.001
Local disease	18	6	2	1
Distant metastases	3	1	4	6

Data are presented as mean ± SD or median (range).

^aoff L-thyroxine therapy.